Eagle Venture Fund

Eagle Venture Fund is an early-stage venture capital firm with website, LinkedIn, and Crunchbase footprint, with positioning that suggests a U.S.-based regional or thematic fund. The source data does not disclose specific stage, sector, healthcare exposure, or check size detail. Without firm-specific verification, healthcare AI founders should treat Eagle as a generalist early-stage investor with no confirmed healthcare specialization. Plausible check sizing at this profile is $250K to $1.5M at seed and small Series A, often as a co-investor though potentially leading smaller rounds in the firm’s home geography. For healthcare AI founders, the most plausible fit, if any, is for software-style healthcare AI companies with capital-efficient unit economics, rather than biotech, regulated devices, or care delivery models requiring deep clinical or payer expertise. Founders building deeply clinical or regulatory-heavy products should look to specialist healthcare investors first. The firm’s value-add is harder to predict without disclosed thesis or recent portfolio data; founders should ask directly during initial outreach about healthcare exposure and recent investments. Entry path is LinkedIn outreach to the partners, the website inquiry form, or warm referral from a portfolio CEO. Founders should reverse-diligence by asking for recent investments, fund size, ownership targets, and any healthcare track record before significant pitch preparation. Be honest about the data gap: at this level of public signal, founder time should be limited until clearer signals of thesis alignment surface. Prioritize disclosed-thesis healthcare investors above this profile in fundraising sequencing, and treat Eagle as opportunistic capacity if and when a conversation surfaces clear interest.